Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

华泰联合证券有限责任公司 关于浙江九洲药业股份有限公司 部分募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为浙江九洲药业股份有限公司（以下简称"九洲药业"或"公司"）非公开发 行股票持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》《上海 证券交易所股票上市规则》《上市公司募集资金监管规则》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等有关规定，对九洲药业部分募投项目 延期进行审慎核查，具体核查情况如下： 一、募集资金基本情况 虽然公司募投项目"瑞博（苏州）制药有限公司研发中心项目"已在前期经 过了充分的可行性论证，但在实际建设过程中仍存在较多不可控因素，主要是受 工程结算进度等因素影响，基于谨慎性考虑，结合当前募集资金投资项目建设情 况，为维护全体股东和公司利益，公司决定将上述募投项目达到预定可使用状态 时间相应延期。 三、本次部分募投项目延期的情况及原因 根据募集资金实际使用和募投项目实际实施情况，为保证募投项目建设更符 合公司和股东利益，公司拟将募投项目"瑞博（苏州）制药有限公司研发中心项 目"的达到预定可使用状态日期由 2025 ...

华泰联合证券有限责任公司 关于浙江九洲药业股份有限公司 使用闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 浙江九洲药业股份有限公司（以下简称"九洲药业"或"公司"）非公开发行股票持 续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易 所股票上市规则》《上市公司募集资金监管规则》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》等有关规定，对九洲药业使用闲置募集资金进行 现金管理进行审慎核查，具体核查情况如下： 一、 投资情况概述 （一）投资目的 公司及子公司为提高资金的使用效率和收益，在保证募集资金项目投资计划 正常实施的情况下，合理利用闲置募集资金购买安全性高、流动性好的投资产品 （包括但不限于结构性存款、定期存款、大额存单、通知存款、收益凭证及银行 或券商理财产品等），不得为非保本型，实行现金管理为公司和股东谋取更好的 投资回报。 （二）投资金额 公司及子公司拟使用不超过人民币 10 亿元的闲置募集资金购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存 款、收益凭证及银行或券商 ...

关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好的投资产品（包括但不限于结构性存款、 定期存款、大额存单、通知存款、收益凭证及银行或券商理财产品等)。 投资金额：浙江九洲药业股份有限公司（以下简称"公司"）及子公司 拟使用不超过人民币12亿元的闲置自有资金进行现金管理，期限为自董事会审议 通过之日起不超过12个月，在上述额度及决议有效期内，可循环滚动使用。 证券代码：603456 证券简称：九洲药业 公告编号：2025-073 浙江九洲药业股份有限公司 履行的审议程序：2025年12月9日，公司召开第八届董事会第十九次会议、 第八届审计委员会第十三次会议，审议通过了《关于使用闲置自有资金进行现金 管理的议案》。 特别风险提示：公司及子公司本次使用闲置自有资金进行现金管理，仅 投资于安全性高、流动性好的投资产品，投资风险可控；但金融市场受宏观经济、 市场波动的影响，不排除投资收益具有一定的不可预期性。 一、自有资金现金管理情况概述 (一) 投资目 ...

浙江九洲药业股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 9 日，浙江九洲药业股份有限公司（以下简称"公司"）第八 届董事会第十九次会议、第八届董事会审计委员会第十三次会议审议通过了《关 于部分募投项目延期的议案》，同意公司根据 2020 年度非公开发行股票部分募投 项目实施的具体情况，将"瑞博（苏州）制药有限公司研发中心项目"达到预定 可使用状态的时间延期至 2026 年 12 月 31 日。具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准浙江九洲药业股份有限公司非公开发 行股票的批复》（证监许可[2021]97 号）文件批复，公司非公开发行人民币普通 股（A 股）股票 26,171,159 股，发行价格为 38.21 元/股，募集资金总额为人民币 999,999,985.39 元，扣除各项发行费用人民币 9,380,611.68 元（不含税），实际募 集资金净额为人民币 990,619,373.71 元。上述募集资金到位情况已经天健 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-072 浙江九洲药业股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好的投资产品（包括但不限于结构性存款、 定期存款、大额存单、通知存款、收益凭证及银行或券商理财产品等），不得为 非保本型。 投资金额：浙江九洲药业股份有限公司（以下简称"公司"）及子公司拟 使用不超过人民币 10 亿元的闲置募集资金进行现金管理，期限为自董事会审议 通过之日起不超过 12 个月，单笔投资产品的期限不超过 12 个月。 已履行的审议程序：2025 年 12 月 9 日，公司召开第八届董事会第十九次 会议、第八届审计委员会第十三次会议，审议通过了《关于使用闲置募集资金进 行现金管理的议案》。 特别风险提示：公司及子公司本次使用闲置募集资金进行现金管理，仅 投资于安全性高、流动性好的投资产品，投资风险可控；但金融市场受宏观经济、 市场波动的影响，不排除投资收益具有一定的不可预期性。 一、投资情 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-070 浙江九洲药业股份有限公司 第八届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江九洲药业股份有限公司（以下简称"公司"）第八届董事会第十九次会议 于 2025 年 12 月 9 日以现场表决结合通讯表决的方式召开。本次董事会已于 2025 年 12 月 4 日以电子邮件、电话等方式通知全体董事、高级管理人员。会议应出 席董事 9 人，实际出席董事 9 人。全体董事推举董事长花莉蓉女士主持本次会议， 本次会议参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关 规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于部分募投项目延期的议案》； 2、审议通过了《关于使用闲置募集资金进行现金管理的议案》； 公司董事会同意公司及子公司在保障资金安全及确保不影响募集资金投资 项目建设和使用计划的前提下，使用不超过人民币 10 亿元的闲置募集资金在自 董事会审议通过之日起 12 个月内购买安全性高 ...

九洲药业公告称，2025年12月9日，公司召开相关会议审议通过议案，同意公司及子公司使用不超12亿 元闲置自有资金，自董事会审议通过之日起12个月内购买安全性高、流动性好的投资产品，如结构性存 款等，且不得用于质押和证券投资。额度内资金可循环滚动使用。公司称投资风险可控，但收益有不可 预期性。 ...

Group 1: New Materials Industry - The rare earth magnetic materials industry rebounded by 2.6% last week, outperforming the benchmark by 0.96 percentage points, with the industry valuation (TTM P/E) rising to 71.79x, currently at 85.5% of its historical percentile [4] - Last week, the prices of rare earth concentrates generally rebounded, with praseodymium and neodymium prices continuing to rise, dysprosium prices declining, and terbium prices weakening [5] - The price of sintered NdFeB (N35) increased by 3.64% last week, while H35 rose by 2.41%, supported by strong demand from downstream orders [7] - The supply side of the rare earth sector is generally tight, with some separation enterprises experiencing reduced operating rates due to maintenance or raw material issues, leading to a tight supply of oxides [8] - The overall market sentiment is characterized by a standoff, but the supply side is expected to decrease while the demand side shows a steady upward trend, indicating that rare earth prices are likely to remain stable with a slight upward bias [8] Group 2: Medical Services Industry - The report highlights that the company is a leading CDMO (Contract Development and Manufacturing Organization) driven by innovation, with revenue growing from 2.017 billion yuan in 2019 to 5.161 billion yuan in 2024, reflecting a CAGR of 20.67% [11] - The revenue from contract custom business has been increasing, with its share rising from 37.55% in 2019 to 75.00% in 2024, indicating a strong focus on this segment [12] - The global CDMO market has maintained a high level of prosperity, with the market size growing from $44.6 billion in 2018 to $79.7 billion in 2023, and is expected to reach $168.4 billion and $338.5 billion by 2028 and 2030, respectively [14] - The company is actively expanding its project pipeline, particularly in peptide and conjugated nucleic acid technologies, which are expected to drive future growth [15] - The company is projected to achieve revenues of 5.670 billion, 6.278 billion, and 6.957 billion yuan from 2025 to 2027, with corresponding net profits of 930 million, 1.031 billion, and 1.147 billion yuan, indicating a positive long-term outlook [16]

Group 1 - The core viewpoint of the article is that Jiuzhou Pharmaceutical is actively expanding its global market presence by establishing a wholly-owned subsidiary in Japan to invest in a CRO service platform, with positive business progress and growth in both clients and projects [1] Group 2 - The company plans to set up the subsidiary in early 2024 [1] - The business development is reported to be progressing smoothly, indicating a favorable operational environment [1] - There is a notable increase in both the number of clients and projects, reflecting strong demand and growth potential [1]